samedan logo
 
 
 
spacer
home > ebr > summer 2021 > accelerating ov immunotherapeutic innovation to market
PUBLICATIONS
European Biopharmaceutical Review

Accelerating OV Immunotherapeutic Innovation to Market

Leveraging the process and analytical expertise of specialised external CDMO partners early in development of oncolytic viruses (OVs) has become a beneficial strategy in providing additional capabilities and insights for many biotech companies approaching this type of cancer treatment.

What science and capabilities are key to creating OVs with safe, efficacious, and robust processes to produce OV programmes? Why it is critical to find specialised commercial partners, and how is best to engage them in the dynamic sector of oncological immunotherapeutic science?

Global spending on cancer therapies and supportive care drugs is expected to reach $200 billion by 2022 (1). With an estimated 18 million cancer cases around the world in 2018, cancer is a leading cause of death and has become an enormous social burden (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Before Vibalogics, Kai Lipinski PhD served as Principal Scientist at Cobra Biologics, focusing on upstream process development for virus and mammalian protein expression projects. Prior to that, Kai worked as Senior Principal Scientist at ML Laboratories, where he was responsible for the development of targeted adenoviral vectors for cancer gene therapy approaches. As Chief Scientific Officer at Vibalogics, Kai is central to the establishment of virus process development and manufacturing capabilities, technical developments, and the acquisition of many key clients.

Kai has a PhD in Transcriptional Regulation by Adenoviral E1A Proteins, and a Post-Doctorate, also on Transcriptional Regulation, from the University of Duisburg-Essen, Germany
spacer
Kai Lipinski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement